Q3 FY2026 · ended Sep 30, 2026 · Revenue $24.55M, -19.1% YoY · Filed Nov 3, 2026
RxSight, Inc. (RXST) files with the SEC under industry code 3851, Ophthalmic Goods. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $24.5 million and a net loss of $16.2 million. Free cash flow was $44.0 million. As of Sep 30, 2026 it held $254.7 million in cash and investments and $10.3 million in total debt.
Revenue
$24.55M
-19.1% vs year-ago quarter
Net income
$-16.22M
-65.3% vs year-ago quarter
Operating cash flow
$45.22M
+3909.3% vs year-ago quarter
Free cash flow
$44.04M
+2591.1% vs year-ago quarter
EPS
$-0.39
-62.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
41.93M
+2.0% vs year-ago quarter
Net cash
$244.36M
Q3 FY2026
Operating margin
-53.3%
TTM
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- RXST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1111485
- Former names
- CALHOUN VISION INC (until Mar 20, 2014)
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Bausch & Lomb Corp BLCO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- Staar Surgical Co STAA
- Innovative Eyewear Inc LUCY
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $24.5M | $27.2M | $30.9M | $32.6M | $30.3M |
| Operating income | -$18.5M | -$13.8M | -$17.8M | -$11.3M | -$12.2M |
| Net income | -$16.2M | -$12.1M | -$15.9M | -$9.2M | -$9.8M |
| Diluted EPS | -$0.39 | -$0.29 | -$0.38 | -$0.22 | -$0.24 |
| Operating cash flow | $45.2M | -$9.5M | -$10.9M | -$1.1M | -$1.2M |
| Free cash flow | $44.0M | -$11.5M | -$11.7M | -$2.3M | -$1.8M |
| Total assets | $340.4M | $352.7M | $304.0M | $311.8M | $308.5M |
| Total liabilities | $85.5M | $89.4M | $36.7M | $36.1M | $32.6M |
| Stockholders' equity | $254.9M | $263.3M | $267.3M | $275.7M | $276.0M |
| Cash and investments | $254.7M | $208.8M | $217.9M | $228.1M | $227.5M |
| Total debt | $10.3M | $10.6M | $10.8M | $11.0M | $11.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 15, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 6, 2026 | Jun 30, 2026 |
All 474 RxSight, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.